KR950011547B1 - Slide and its manufacturing method on anti-nuclear antibody diagnosis - Google Patents

Slide and its manufacturing method on anti-nuclear antibody diagnosis Download PDF

Info

Publication number
KR950011547B1
KR950011547B1 KR1019920012928A KR920012928A KR950011547B1 KR 950011547 B1 KR950011547 B1 KR 950011547B1 KR 1019920012928 A KR1019920012928 A KR 1019920012928A KR 920012928 A KR920012928 A KR 920012928A KR 950011547 B1 KR950011547 B1 KR 950011547B1
Authority
KR
South Korea
Prior art keywords
cells
slide
cell line
hep
cell
Prior art date
Application number
KR1019920012928A
Other languages
Korean (ko)
Other versions
KR940002610A (en
Inventor
김신규
Original Assignee
김신규
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김신규 filed Critical 김신규
Priority to KR1019920012928A priority Critical patent/KR950011547B1/en
Priority to AU45871/93A priority patent/AU4587193A/en
Priority to DE69330160T priority patent/DE69330160T2/en
Priority to JP50436094A priority patent/JP3721581B2/en
Priority to PCT/KR1993/000061 priority patent/WO1994002594A1/en
Priority to EP93916262A priority patent/EP0604635B1/en
Priority to ES93916262T priority patent/ES2156127T3/en
Priority to US08/196,220 priority patent/US5583053A/en
Publication of KR940002610A publication Critical patent/KR940002610A/en
Application granted granted Critical
Publication of KR950011547B1 publication Critical patent/KR950011547B1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The slide for detecting antinuclear antibodies (ANA) contains a macrophage cell line immobilised in wells. The method may be used for diagnosis of autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis and rhematoid arthritis. The specified cell line, namely IT-1 (KCCM 10038), has better glass adhesion that HEp-2 (a tumour cell line), is derived from normal bone marrow, and does not give the false negative associated with HEp-2 ('ANA negative lupus')

Description

[발명의 명칭][Name of invention]

항핵항체 진단용 슬라이드 및 그의 제작방법Anti-nuclear antibody diagnostic slide and its manufacturing method

[발명의 상세한 설명]Detailed description of the invention

본 발명은 항핵항체(anti-nuclear antiody;이하 ANA로 약함)의 진단용 IT-1 세포주를 개발하고, 배양한 세포주를 이용하여 ANA 진단용 슬라이드 및 그의 제작방법에 관한 것이다.The present invention is directed to the development of diagnostic IT-1 cell lines for anti-nuclear antibodies (hereinafter, weakly referred to as ANA), ANA diagnostic slides, and a method for producing the same.

혈청내 자가항체의 존재를 검사하는 ANA 진단은 자가면역질환인 전신성 홍반성 낭창(systemic lupus erythematusus; 이하 SLE로 약함), 쉐그렌(Sjoegren)증후군, 경피증, 혼재성 교원병, 류마티스성 관절영, 소아 만성 다발성관절염(juvenile chronic polyarthritis)과 그 밖의 자가 면역성 질환등의 전신성 류마티스 질환에 적응된다. 1948년 하그레이브스가 LE세포를 발견한 이후, 1980년대에서는 형광항체법에 의한 염색패턴과 이중면역확산법(double immuno-diffusion method)등의 기술이 도입되어, ANA에 대한 핵항원으로 DNA, 히스톤, 추출성 핵항원(extractile nuclear antigen:ENA), 예를들어 Sm(Smith), nRNP(nuclearribonucleoprotein), as-A (Sjoegren associated antigen), ss-B, scl-70(scleroderma) 등과 인등이 밝혀졌다. ANA 진단에 의해 일차로 자가면역질환 판정을 받은 환자는 각 항원에 대한 구체적인 항체검정시험에 착수하여 병명을 결정한다.The ANA diagnosis, which examines the presence of autoantibodies in serum, includes systemic lupus erythematusus (weak SLE), Sjoegren's syndrome, scleroderma, mixed collagen, rheumatoid arthritis, and children It is adapted to systemic rheumatoid diseases such as juvenile chronic polyarthritis and other autoimmune diseases. After Hargraves discovered LE cells in 1948, in the 1980s, techniques such as staining patterns and double immuno-diffusion methods by fluorescent antibody methods were introduced, and DNA, histone, Extractive nuclear antigens (ENA), for example Sm (Smith), nRNP (nuclearribonucleoprotein), as-A (Sjoegren associated antigen), ss-B, scl-70 (scleroderma) and the like has been found. Patients who are primarily diagnosed with autoimmune disease by ANA diagnosis should undertake specific antibody assays for each antigen to determine disease name.

ANA 진단방법을 개괄적으로 설명하면, 고정된 기질(정상적인 포유류의 조직 또는 세포내)에 존재하는 항원에 대하여 환자 혈액내에 존재하는 항체를 결합시킨 뒤, 결합한 항체를 형광을 이용하여 관찰하는 것이다. 따라서 진단은 다음의 단계를 거치게 된다.The ANA diagnostic method is generally described by binding an antibody present in the patient's blood to an antigen present in a fixed substrate (normal mammalian tissue or cell), and then observing the bound antibody using fluorescence. Therefore, the diagnosis goes through the following steps.

1) 기질의 부착 : 현미경 관찰을 위해 슬라이드에 기질을 부착시키는 것으로, 쥐의 간등 조직을 냉동시킨 뒤 냉동조직절편을 슬라이드로 직접 옮기거나, HEp-2(인체상피세포), BHK(어린 햄스터신장세포), KB(인체 KB신장)등 세포주를 사용하는 경우에는 슬라이드 위에서 무균적으로 배양한 슬라이드를 사용한다. 후자의 경우 외국에서 상품화된 슬라이드를 사용할 수 있다.1) Attachment of Substrate: Attaching the substrate to the slide for microscopic observation. After freezing the rat's liver tissue, the frozen tissue section is transferred directly to the slide, or HEp-2 (human epithelial cell), BHK (young hamster kidney) When using cell lines such as cells) or KB (human KB kidney), slides cultured aseptically on the slides are used. In the latter case, you can use commercialized slides.

2) 부착된 기질의 고정 : 혈액과의 반응후 세척시 기질이 떨어져 나가는 것을 방지하기 위해 슬라이드에 부착시키는 효과와, 반응이 잘 일어나도록 기질 세포들이 지질막을 성글게 만드는 효과가 나타나도록 처리한다.2) Fixation of the attached substrate: After washing with the blood, the substrate is treated to prevent the substrate from falling off.

3) 환자 혈청과의 반응 : 1:20에서 1:1280으로 2배수 희석한 환자의 혈청을 고정화된 기질과 반응시키며, ANA 표준 혈청에 대하여 대조실험을 실시한다.3) Reaction with Patient Serum: Serum from patients diluted 2-fold from 1:20 to 1: 1280 is reacted with immobilized substrate and a control experiment is performed on ANA standard serum.

4) 고습도에서 30분간 실온에서 반응시킨 후 인산완충액으로 세척, 건조.4) After reacting at room temperature for 30 minutes at high humidity, it is washed with phosphate buffer and dried.

5) 1차 항체에 대한 항-면역글로블린을 투여 : ANA 검사에서는 주로 면역형광방법이 사용되며, 본 발명에서는 인간 감마 글로블린에 대한 토끼 항체를 FITC로 라벨시킨 다코(Dako)사 제품을 사용하였다.5) Administration of anti-immunoglobulin to the primary antibody: The immunofluorescence method is mainly used in the ANA assay, and in the present invention, a Dako Corporation product, which is a rabbit antibody to human gamma globulin, is labeled with FITC.

6) 인산완충액으로 10분간 세척 후, 에반스 블루로 염색, 인산완충액으로 다시 세척.6) Wash with phosphate buffer for 10 minutes, stain with Evans blue, wash again with phosphate buffer.

7) 형광현미경으로 관찰하여 판독하는 과정을 거치게 된다. 일반적인 진단방법에서는 형광물질을 이용하는 면역형광방법과 효소반응을 이용하는 면역효소방법이 적용되지만, ANA 검사에서는 전자의 방법이 많이 적용된다.7) Observed by fluorescence microscope to read. In general diagnostic methods, immunofluorescence method using fluorescent material and immunoenzyme method using enzyme reaction are applied, but the former method is applied to ANA test.

ANA 검사에 있어서 정확도를 높이기 위해서는, 1) 검사방법과 정량, 2) 기질과 고정액의 선택, 3) 정상범위의 확립과 검사결과의 판독능력등을 고려해야 한다. 1982년 AF-CDC(항핵항체에 대한 혈청 표준화 회의; Arthritis Rheum. 25, 1003, 1982)에서 표준 혈청을 개발함으로써 1)항에 있어서의 문제점인 항체의 특성과 역가가 표준화되었고, 동시에 형광의 등급이 결정된 슬라이드를 이용함으로써 면역형광방법을 활용하는 검사에 있어서의 형광현미경간의 불일치나 질적인 차이, FITC와 결합한 항혈청의 농도, 형광물질과 단백질과의 혼합비등이 개선되었다.To improve accuracy in ANA testing, consideration should be given to 1) test methods and quantification, 2) selection of substrates and fixatives, 3) establishment of normal ranges and the ability to read test results. By developing standard sera in AF-CDC (Sera Standardization Meeting for Antinuclear Antibodies; Arthritis Rheum. 25, 1003, 1982) in 1982, the characteristics and titers of the antibody, which is a problem in paragraph 1), were standardized and at the same time grade of fluorescence By using the determined slides, inconsistencies and qualitative differences between fluorescence microscopes, the concentration of antiserum bound with FITC, and the mixing ratio of fluorescent substances and proteins were improved.

냉동조직절편(cryostat tissue section)이나 배양된 세포(cultured cells)를 이용하는 기질에 대한 연구는 아직도 개발의 여지가 많다. 배양된 포유류 세포, 예를 들어 백서의 조직아세포인 MF, 원숭이 신장세포인 VMK, 사람의 세포인 HA, KB, HEp-2(ATCC CLL 23로 기탁되어 있다)등은 백서를 위시한 실험동물의 간장과 신장등 장기를 이용하는 냉동조직절편에 비하여 다음과 같은 이점이 있다. 배양된 세포는 냉동조직 절편보다 일반적으로 핵의 크기가 크고, 특정 핵항원의 함유량이 높고 다양해 형광양상의 판독이 용이하고 위음성의 가능성이 훨씬 낮다. 또 다른 장점은 세포주를 슬라이드에서 배양하면 분열증인 세포를 관찰할 수 있으며, 이를 이용하여 항 entromere 항체, 증식세포에서만 관찰되는 핵항원(proliferating cell nuclear antigen; PCNA) 등의 진단과 감별하기 어려운 형광양상을 보면 객관적으로 확진할 수 있다. 냉동조직절편은 種-屬 특이성이나 장기특이성을 나타내고 있다. 이상의 관점에서 배양세포를 이용한 슬라이드를 기질로 사용하는 것이 유리하며, 칼리스타드사(Kallestad), 베링진단사 (Behring Diagnostic), 일본의 엠비엘사(MBL) 등의 회사에서 Hep-2 세포를 배양하여 부착한 슬라이드를 판매하고 있다. 이상의 관점에 대하여 발명자는 대한내과학회잡지, 제35권 제3호(1988년) 315면을 통해 "HEp-2 세포배양을 이용한 항핵항체 검사에 관한 연구"라는 제목으로 발표한 바 있다.Research into substrates using cryostat tissue sections or cultured cells is still in development. Cultured mammalian cells such as histoblast's tissue blast MF, monkey kidney cells VMK, human cells HA, KB, HEp-2 (deposited as ATCC CLL 23), etc. Compared to frozen tissue sections using organs such as and kidneys has the following advantages. Cultured cells generally have larger nuclei, higher levels of specific nuclear antigens, and more diverse than frozen tissue sections, making them easier to read and less prone to false negatives. Another advantage is that if the cell line is cultured on a slide, the schizophrenic cells can be observed, and fluorescence patterns that are difficult to distinguish from the diagnosis of anti-entromere antibodies and proliferating cell nuclear antigens (PCNA) only observed in proliferating cells are used. Can be objectively confirmed. Frozen tissue slices show VIII-VII specificity or organ specificity. In view of the above, it is advantageous to use a slide using culture cells as a substrate, and Hep-2 cells are cultured and attached by companies such as Kallestad, Behring Diagnostic, and MBL of Japan. Sell slides. In view of the above, the inventors of the Korean Society of Internal Medicine, Vol. 35, No. 3 (1988), p. 315, entitled "A Study on Antinuclear Antibody Test Using HEp-2 Cell Culture".

그러나 배양세포 슬라이드를 수입하여 사용하는 것은 값이 비싸고, 배양된 세포인 HEp-2 세포는 인간에서 유래된 세포이기는 하지만 후두암에서 분리된 것이며 슬라이드 배양시 부착율이 만족스럽지 않으므로, 이상의 결점을 개선하기 위하여 질병이 는 정상인에서 유래된 부착성의 세포를 개발하고자 연구를 계속하던 중, 3년간의 배양기간에서도 안정하여 부착력이 뛰어난 세포주를 얻었기에 본 발명을 완성하였다. 접착력이 우수하여 슬라이드 준비시 불량율이 낮으며, 보다 낮은 세포농도로 슬라이드를 제작할 수 있었다. HEp-2 세포주와 대비하여 ANA 진단의 결과를 비교하여 보았을 때 ANA 진단 허용 범위내에 존재하였다. 특히 개발된 세포주는 여러 배양조건에서도 잘 자란다는 특성을 나타내었다. 이후 본 발명에 관하여 상세히 설명하지만, 새로운 세포주에 대한 특성은 실시예 에만 국한되는 것은 아니다.However, importing and using culture cell slides is expensive, and the cultured cells, HEp-2 cells, are human-derived cells but are isolated from laryngeal cancer and are not satisfactory in adherence in slide culture. In order to develop an adherent cell derived from a normal disease for the disease, the present invention was completed because it was stable even in the culture period of 3 years to obtain a cell line with excellent adhesion. Excellent adhesion, low failure rate during the slide preparation, it was possible to produce a slide at a lower cell concentration. The results of the ANA diagnosis compared to the HEp-2 cell line were present within the ANA diagnosis tolerance range. In particular, the developed cell lines showed good growth under various culture conditions. Hereinafter, the present invention will be described in detail, but the characteristics of the new cell line are not limited to the examples.

[실시예 1]Example 1

세포주의 분리Isolation of Cell Lines

정상인의 골수를 무균적으로 천자하여 골수세포액을 채취하고, 시그마사의 히스토팍(Histopaque) 1077이 담겨져 있는 원심분리관에 옮긴 뒤, 20도씩 400g에서 30분간 원심분리하여 단핵세포만을 얻었다. 10% 송아지 혈청을 추가한 RPMI-1640 (Gibco사 제품) 15 밀리리터를 함유하고 있는 75 평방센터미터의 배양플라스크에 분리한 단핵세포를 접종하여 5% 탄산개스로 조절된 37도씨 배양기에서 3일간 배양하고, 부착되지 않은 림포사이트등의 단핵세포를 배양액으로 세척하여 제거하였다. 배양기에 부착된 세포들은 20% 송아지 혈청을 추가한 RPMI-1640으로 계속 증식시켰고, 5일후 2차로 트립신을 처리한 뒤 4개의 배양기에 분지하여 배양하였다. 배양액을 3일마다 교환하였고, 28일뒤에는 송아지 혈청을 10%로 낮춘 배양액을 사용하여 배양하였다. 이로써 단핵세포/마크로파지(moncoyte/macrophage)계세포주 IT-1을 얻게 되었다. 이 세포주는 1989년 6월부터 현재까지 잘 자라고 있으며, 1992년 7월 15일 KFCC-10772로 기탁되었다. (Ham's)F12K 배지나 돌베코의 배지(Dulbecco's Modified Eagle's Medium; 이하 DMEM로 약함)에서도 잘 자라고, 송아지 혈청 5%를 첨가한 RPMI-1640에서도 배양가능하였다. 특히 비타민등의 첨가제를 별도로 요구하지 않으며, 10% 송아지 혈청을 첨가한 RPMI-1640에서는 1×105/ml로 0.1 밀리리터를 접종하면 5일후 빽빽하게 자라 증식력도 우수하였다.Bone marrow was obtained by aseptic puncture of normal human bone marrow, and then transferred to a centrifuge tube containing Sistoma's Histopaque 1077, followed by centrifugation at 400 ° C. for 30 minutes at 20 degrees to obtain only mononuclear cells. RPMI-1640 (10% calf serum) (Gibco Co., Ltd.) 15 days inoculated with the isolated mononuclear cells in a 75 square center culture flask containing 3 ml in a 37 ° C incubator controlled with 5% carbonated gas Cultured and unattached mononuclear cells such as lymphocytes were removed by washing with culture. Cells attached to the incubator continued to proliferate with RPMI-1640 added with 20% calf serum, and after 5 days of trypsin treatment, branched to four incubators. The cultures were exchanged every 3 days and after 28 days the cultures were incubated with a 10% calf serum. This resulted in the mononuclear cell / macrophage cell line IT-1. The cell line is growing well from June 1989 to the present and was deposited on July 15, 1992 as KFCC-10772. It grew well in (Ham's) F12K medium or Dolbecco's medium (weakly referred to as DMEM) and cultured in RPMI-1640 with 5% calf serum. In particular, the additives such as vitamins are not required separately, and in the RPMI-1640 to which 10% calf serum was added, 1 × 10 5 / ml of 0.1 milliliters was inoculated densely after 5 days and showed excellent growth ability.

[실시예 2]Example 2

슬라이드의 준비Preparation of the slide

배양된 IT-1 세포액을 2×104cell/ml 되도록 10% 송아지 혈청을 첨가한 RPMI-1640 배지로 희석한 뒤, 12개의 구멍이 그려져 있는 IF 슬라이드를 멸균하고 각 구멍에 희석액 3마이크로리터를 접종하였다. 5% 탄산개스로 조절된 37도씨 배양기에서 24시간 배양하였다. 각 슬라이드에서 배양액을 제거하고, 인산완충액으로 세척한 뒤, 95% 메탄올에 10분간 담궈 세포들을 고정하였다. 이렇게 준비된 슬라이드는 4도씨에서 1년 정도 보관 가능하였다.After diluting the cultured IT-1 cell solution with RPMI-1640 medium to which 10% calf serum was added to 2 × 10 4 cells / ml, sterilized IF slides with 12 holes and 3 microliters of dilutions in each hole. Inoculation. It was incubated for 24 hours in a 37 ° C incubator controlled with 5% carbon dioxide. Cultures were removed from each slide, washed with phosphate buffer, and soaked in 95% methanol for 10 minutes to fix cells. The slides thus prepared could be stored at 4 degrees for about a year.

[비교실시예 ]Comparative Example

HEp-2 세포를 이용한 슬라이드의 준비Preparation of Slides Using HEp-2 Cells

시판되고 있는 IF 슬라이드가 HEp-2 세포를 사용하고 있으므로, 이 세포주를 배양하여 슬라이드를 준비하는 방법을 비교실시예 로 택하였다. HEp-2 세포세포를 1×105cell/ml 되도록 10% 송아지 혈청이 첨가된 DMEM 배지로 희선학 뒤, IF 슬라이드에 30마이크로리터를 접종하였다. 세포가 갈아앉아 세포가 부착하면 접종액을 제거하고, 추가로 배지를 30마이크로리터를 각 구멍에 분지하고, 실시예 1과 같은 방법으로 배양하였다. 배지를 제거한 후, 인산완충액으로 세척하고, 95% 메탄올에 10분간 담궈 고정하였다.Since commercially available IF slides use HEp-2 cells, a method of preparing the slides by culturing this cell line was selected as a comparative example. Hep-2 cell cells were lined with DMEM medium with 10% calf serum added to 1 × 10 5 cells / ml, followed by inoculation of 30 microliters on the IF slide. When the cells changed and the cells adhered, the inoculum was removed, and 30 microliters of the medium was further branched into each hole, and cultured in the same manner as in Example 1. After removing the medium, it was washed with phosphate buffer, soaked in 95% methanol for 10 minutes and fixed.

[실시예 3]Example 3

세포주를 이용한 ANA 진단ANA diagnosis using cell line

실시예 1, 비교실시예 와 판매되는 제품의 슬라이드에 1:20부터 1:1280으로 2배수 희석한 류마티스 환자의 혈청 시료 30마이크로리터를 떨어뜨리고, 고습도에서 30분간 실온에서 반응시킨 뒤, 인산완충액이 채워진 크프란병에 넣고 진탕기로 분당 200rpm으로 진탕하여 세척하고 건조시켰다. 대조군으로 AF-CDC 표준혈청 #1, #2, #3, #6을 사용하였다. 1:40으로 희석된 FITC로 라벨화된 인간 감마 글로블린에 대한 토끼 항체(Dako사 제품) 30 마이크로리터를 각 슬라이드에 적용하여 고습도의 실온에서 30분간 반응시켰다. 인산완충액으로 10분간 세척하고, 0.2%에 반스블루용액(방부제를 가하여 4도씨에서 보관한다)로 카운터 염색한 뒤, 인산완충액으로 세척하였다. 남아있는 인산완충액은 여과지를 사용하여 흡수시키고, 글리세롤을 사용하여 형광현미경으로 400배에서 관찰하였다.Example 1, Comparative Example and 30 microliters of serum samples of rheumatoid patients diluted 2-fold from 1:20 to 1: 1280 were dropped on the slides of the product sold, and reacted at room temperature for 30 minutes at high humidity, followed by phosphate buffer solution. Into this filled Cran bottle, shaken with a shaker at 200rpm per minute and dried. AF-CDC standard serum # 1, # 2, # 3, # 6 was used as a control. 30 microliters of a rabbit antibody (manufactured by Dako) against human gamma globulin labeled with FITC diluted 1:40 was applied to each slide and allowed to react for 30 minutes at room temperature with high humidity. Washed with phosphate buffer for 10 minutes, counter-stained with a Vans Blue solution (preserved at 4 ° C.) at 0.2%, and washed with phosphate buffer. The remaining phosphate buffer was absorbed using filter paper and observed at 400-fold by fluorescence microscope using glycerol.

현미경 관찰시의 형광양상은 표준혈청 #1에 대해서는 휴식세포나 분열세포들은 모두 전체적으로 또는 세포둘레에만 염색되었고, 표준혈청 #2, #3에 대해서는 부분적으로 염색되지 않는 스펙클드(speckled) 형태이며, 표준혈청 #6에 대해서는 핵소체형(nucleolar)으로 염색되었다. 표준혈청 #2, #3, #6의 결과는 휴식세포에서만 관찰된 것이다. 이는 AF-CDC에서 제시한 형광양상과 일치하였다.The fluorescence pattern under the microscope is a speckled form in which both resting cells and dividing cells are stained as a whole or only around the cells for standard serum # 1, and not partially stained for standard serum # 2 and # 3. For standard serum # 6, it was stained with nucleolar. The results of standard serum # 2, # 3 and # 6 were observed only in resting cells. This is consistent with the fluorescence pattern presented by AF-CDC.

또한 형광의 세기를 강한 경우 4+, 충분한 경우를 3+으로, 1+은 거의 식별할 수 있는 정도로 구분하여 희석배율에 따른 역가를 비교한 결과는 표와 같다. HEp-2 세포의 경우 표준혈청 #1과 #2, #6은 1:320, #3은 1:640의 희석비율에서 충분한 형광을 나타내었고, IT-1 세포의 경우에서도 같은 양상을 보였다. AF-CDC에서는 표준혈청 #1, #3에 대하여 1:160에서 1:640, #2, #6에 대하여 1:80에서 1:320의 환자 혈액의 희석비를 추천하고 있는데, 두 세포 모두 추천범위 내에 속하였다. 그러나 형광이 겨우 검출되는 희석배율을 살펴보면, 표준혈청 #1의 경우 HEp-2는 1:640, IT-1는 1:1280; #2의 경우 HEp-2 1:1280, IT-1는 1:640; #3의 경우 HEp-2는 1:1280 이상의 희석에서도 가능, 2의 경우 IT-1는 1:1280; #6의 경우 HEp-2는 1:1280, IT-1는 1:1280이었다. 그러나 큰 의미는 없다고 본다.In addition, the intensity of fluorescence is divided into 4+ for strong, 3+ for sufficient, and 1+ for an almost discernible amount. HEp-2 cells showed sufficient fluorescence at dilutions of standard serum # 1, # 2 and # 6 at 1: 320, and # 3 at 1: 640. The same pattern was observed for IT-1 cells. AF-CDC recommends a dilution ratio of patient blood from 1: 160 to 1: 640 for standard serum # 1 and # 3, and 1:80 to 1: 320 for # 2 and # 6. It was in range. However, when looking at the dilution rate that fluorescence is only detected, HEp-2 is 1: 640 and IT-1 is 1: 1280 for standard serum # 1; # 2 HEp-2 1: 1280, IT-1 1: 640; For # 3 HEp-2 is also possible at dilutions above 1: 1280, for 2 IT-1 is 1: 1280; For # 6, HEp-2 was 1: 1280 and IT-1 was 1: 1280. But I do not see much meaning.

[표 1]TABLE 1

AF-CDC 표준혈청에 대한 타이터의 비교Titer comparison of AF-CDC standard serum

현미경관찰시 슬라이드의 12개 구멍에 모두 세포가 부착하여 있다면 판독이 용이하지만, 세포가 접착되지 않고 떨어져 나간 경우가 발견되는 불량율을 검토하였을 때, IT-1 세포에서는 9/600이었고, HEp-2 세포에서는 95/600이었다. 이로써 부착력이 우수함을 알 수 있었다.When the cells were attached to all 12 holes of the slide during the microscopic observation, it was easy to read, but when examining the defective rate in which the cells were detached and detached, it was 9/600 in the IT-1 cell and HEp-2. 95/600 in the cells. This shows that the adhesion is excellent.

또한 슬라이드 상에 접종하는 세포의 수도 1/5을, 배양액도 절반을 절약할 수 있었다.In addition, the number of cells inoculated on the slide was reduced by 1/5 and the culture medium was also saved by half.

[실시예 4]Example 4

일상실험에의 응용결과Application result in daily experiment

검사에 대한 양성율을 살펴보면, 백서 신장의 냉동 조직전편을 이용하는 경우 SLE에서 96%, 경피중 40%이며, 사람유래 세포인 HEp-2를 사용하는 경우에는 99%, 88%이었고, 본 발명의 IT-1을 사용하는 경우에는 100%, 95%로 나타나 본 세포주의 우수성을 나타내었다. 혼재성 교원병에 있어서도 100%의 정확성을 나타냈다.The positive rate for the test was 96% in SLE and 40% in transdermal when using frozen whole tissue of white kidney, and 99% and 88% when using HEp-2, a human-derived cell. In the case of using -1, the cell lines showed 100% and 95% superiority. 100% accuracy was also found in mixed collagen disease.

이상에서 살펴볼 때, 질병이 없는 정상인에서 유래된 부착성의 단핵세포 (monocyte/macrophage) 유래 세포주는 3년간의 배양기간에서도 안정하였다. 후두암에서 유래된 HEp-2 세포와 대비할 때 ANA 진단에서 동일한 결과를 얻는 경우, 접종세포의 농도와 배지가 절역되어 값비싼 HEp-2 배양세포 슬라이드를 대체할 수 있게 되었다.In view of the above, the adherent mononuclear cell (monocyte / macrophage) -derived cell line derived from a normal human without disease was stable even for 3 years of culture. When the same results were obtained in ANA diagnosis as compared to HEp-2 cells derived from laryngeal cancer, the concentration and medium of the inoculated cells could be decribed to replace expensive HEp-2 culture cell slides.

Claims (4)

부착성의, 정상인의 골수로부터 유래된 항핵항체 진단용 단핵세포 (monocyte/macrophage) IT-1 세포주(KFCC 1-10772)를 -IF 슬라이드 구멍에 고정시켜서 이루어진 항핵항체 진단용 슬라이드.An antinuclear antibody diagnostic slide formed by fixing an antinuclear antibody diagnostic mononuclear cell (monocyte / macrophage) IT-1 cell line (KFCC 1-10772) derived from bone marrow of a normal person in an -IF slide hole. 정상인의 골수로부터 유래된 부착성 항핵항체 진단용 세포주 IT-1 (KFCC-10772)를 슬라이드 구멍에 접종하여 24시간 배양한 후 완충액으로 세척한 뒤 고정시킴을 특징으로 하는 항핵항체 진단용 슬라이드의 제작방법.A method for producing an anti-nuclear antibody diagnostic slide comprising inoculating a cell line IT-1 (KFCC-10772) for diagnosis of adherent antinuclear antibody derived from bone marrow of a normal person, culturing for 24 hours, washing with a buffer, and fixing the immobilized antinuclear antibody. 제2항에 있어서, 슬라이드 구멍당 104cell/mℓ농도의 세포주를 30마이크로리터로 접종함을 특징으로 하는 항핵항체 진단용 슬라이드의 제작방법.The method according to claim 2, wherein the cell line having a concentration of 10 4 cells / ml per slide hole is inoculated at 30 microliters. 제2항에 있어서, 메탄올로 세포를 고정함을 특징으로 하는 항핵항체 진단용 슬라이드의 제작방법.The method for producing a slide for diagnosing antinuclear antibody according to claim 2, wherein the cell is fixed with methanol.
KR1019920012928A 1992-07-21 1992-07-21 Slide and its manufacturing method on anti-nuclear antibody diagnosis KR950011547B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1019920012928A KR950011547B1 (en) 1992-07-21 1992-07-21 Slide and its manufacturing method on anti-nuclear antibody diagnosis
AU45871/93A AU4587193A (en) 1992-07-21 1993-07-21 Macrophage cell line for an antinuclear antibody test; a method for detecting the said antibody by employing the macrophage cell line and a slide preparation
DE69330160T DE69330160T2 (en) 1992-07-21 1993-07-21 MACROPHAGE CELL LINE FOR ANTINUCLEAR ANTIBODY TEST; A METHOD FOR DETECTING THE SAME ANTIBODY BY USING THIS CELL LINE AND MANUFACTURING SLATS
JP50436094A JP3721581B2 (en) 1992-07-21 1993-07-21 Macrophage cell line for antinuclear antibody test, antibody detection method using macrophage cell line and slide preparation
PCT/KR1993/000061 WO1994002594A1 (en) 1992-07-21 1993-07-21 Macrophage cell line for an antinuclear antibody test; a method for detecting the said antibody by employing the macrophage cell line and a slide preparation
EP93916262A EP0604635B1 (en) 1992-07-21 1993-07-21 Macrophage cell line for an antinuclear antibody test; a method for detecting the said antibody by employing the macrophage cell line and a slide preparation
ES93916262T ES2156127T3 (en) 1992-07-21 1993-07-21 MACROFAGOS CELL LINE FOR AN ANTI-BODY ANTIBODY TEST; A METHOD TO DETECT SUCH ANTIBODIES USING THE MACROPHAGES CELL LINE AND A PREPARATION FOR MICROSCOPE.
US08/196,220 US5583053A (en) 1992-07-21 1993-07-21 Macrophage cell line for use in the detection of antinuclear antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920012928A KR950011547B1 (en) 1992-07-21 1992-07-21 Slide and its manufacturing method on anti-nuclear antibody diagnosis

Publications (2)

Publication Number Publication Date
KR940002610A KR940002610A (en) 1994-02-17
KR950011547B1 true KR950011547B1 (en) 1995-10-06

Family

ID=19336653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920012928A KR950011547B1 (en) 1992-07-21 1992-07-21 Slide and its manufacturing method on anti-nuclear antibody diagnosis

Country Status (1)

Country Link
KR (1) KR950011547B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3760815B2 (en) * 2001-07-27 2006-03-29 株式会社日立製作所 Video display device

Also Published As

Publication number Publication date
KR940002610A (en) 1994-02-17

Similar Documents

Publication Publication Date Title
US3951748A (en) Sensitized matrix for detection of disease
US4332783A (en) Process for immunologic determination tests
EP0094603B1 (en) Enzyme/immunofluorescent assay for autoantibodies
AU621310B2 (en) Immunometric assay kit and method applicable to whole cells
US6638723B1 (en) Method for diagnosing autoimmune diseases
EP1461616A2 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
KR950011547B1 (en) Slide and its manufacturing method on anti-nuclear antibody diagnosis
KR960005733B1 (en) Monocyte/macrophage for detecting anti-nuclear antibody
AU625344B2 (en) Chlamydia half-sandwich immunoassay
Coon et al. Flow cytometric analysis of heterogeneity in blood group-related antigen expression in a human urinary bladder carcinoma cell line, 647V
CN108241064A (en) A kind of kit and its test method for measuring thyroglobulin antibody content
EP0154917A2 (en) Enzyme/immunofluorescent assay for anti-Epstein-Barr virus antibodies
Rector et al. The enumeration of rat IgE‐secreting cells using a reverse plaque‐forming cell assay
JP3721581B2 (en) Macrophage cell line for antinuclear antibody test, antibody detection method using macrophage cell line and slide preparation
JPH09218202A (en) Method and kit for detecting anti-nucleus antibody
Daniels et al. GIL: a red cell antigen of very high frequency
RU2737776C1 (en) Test kit for detecting cholera toxin in cultivation medium
Jonsson The incidence of antibodies to a soluble nuclear antigen in the sera of patients with systematic lupus erythematosus and rheumatoid arthritis estimated with the mixed haemadsorption technique
Wadeleux et al. Thyroid growth modulating factors in the sera of patients with simple non-toxic goitre
EP0241025A1 (en) Method and substrate for immunofluorescent microscopy
CN117110603A (en) Fluorescent immunochromatography test strip for combined detection of anti-MCV antibody, anti-CCP antibody and RF
Manthorpe et al. Anti-Dna Antibody Determination in Systemic Lupus Erythematosus (Sle): Predictive Value as Compared with the LE-Cell Test
JP2892814B2 (en) Assay method for anti-tuberculosis antibody-like substance
Niyazmatov et al. Polymeric Microspheres with Zn Ions on the Surface for Diagnosis of Diseases II. Design of a Latex Diagnostic Test for Detection the Common Endotoxin for Gram-negative Bacteria
CA2012939A1 (en) Assay kit and method applicable to whole cells

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110311

Year of fee payment: 17

EXPY Expiration of term